论文部分内容阅读
目的观察曲美他嗪对慢性心力衰竭(CHF)病人心功能、脑钠肽(BNP)和心肌肌钙蛋白I(cTnI)的影响。方法60例病情稳定的CHF病人,随机分为治疗组及对照组,每组30例。对照组病人采用心力衰竭常规药物治疗,治疗组在对照组治疗的基础上加用曲美他嗪20mg,每日3次,两组均连续治疗4周。观察治疗前后两组NYHA分级、心功能、BNP和cTnI等指标的变化。结果与治疗前相比,两组治疗后NYHA分级及心功能均得到显著改善,血浆BNP及cTnI水平显著降低(P<0.05或P<0.01);与对照组治疗后相比,曲美他嗪组显著缩小病人左室舒张末内径(LVEDD,P<0.05),显著减小左室质量指数(LVMI,P<0.05),显著增加左室射血分数(LVEF,P<0.05);血浆BNP(P<0.05)和cTnI(P<0.01)显著降低。结论曲美他嗪能降低血浆BNP及cTnI水平,改善CHF病人的心功能。
Objective To investigate the effects of trimetazidine on cardiac function, brain natriuretic peptide (BNP) and cardiac troponin I (cTnI) in patients with chronic heart failure (CHF). Methods Sixty CHF patients with stable disease were randomly divided into treatment group and control group, with 30 cases in each group. The patients in the control group were treated with conventional drugs of heart failure. The treatment group was given trimetazidine 20 mg on the basis of the control group three times a day for 4 weeks. Changes of NYHA classification, cardiac function, BNP and cTnI in two groups before and after treatment were observed. Results Compared with those before treatment, NYHA classification and cardiac function were significantly improved after treatment in both groups, and plasma levels of BNP and cTnI were significantly decreased (P <0.05 or P <0.01). Compared with the control group, trimetazidine (LVEDD, P <0.05), significantly decreased left ventricular mass index (LVMI, P <0.05), significantly increased left ventricular ejection fraction (LVEF, P <0.05) P <0.05) and cTnI (P <0.01) significantly decreased. Conclusion Trimetazidine can reduce plasma BNP and cTnI levels and improve cardiac function in CHF patients.